4 completed, 2 terminated, 1 not yet recruiting, 1 recruiting. 4 Phase 3, 2 Phase 2, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Withdrawn 1 |
Follow Antithrombin III Deficiency: new trials by email Literature Review of Antithrombin III Deficiency trials Research Report on Antithrombin III Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belgian Antithrombin Deficiency Registry observation - Antithrombin III Deficiency | Not yet recruiting | Universitair Ziekenhuis Brussel | 1000 | 2025-05-01 | 2024-12-04 | |
| Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass Human plasma derived antithrombin, Placebo - Acquired Antithrombin Deficiency | Phase 3 | Recruiting | Octapharma | 120 | 2024-08-21 | 2026-09-28 |
| Antithrombin III in Infectious Disease Caused by COVID-19 Antithrombin III - Antithrombin III Deficiency, Covid19 | Phase 2 | Terminated | Enrique Ginzburg | 52 | 2021-07-06 | 2022-09-07 |
| Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO Antithrombin III - Antithrombin III Deficiency, Extracorporeal Membrane Oxygenation Complication | Completed | Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital | 50 | 2020-01-01 | 2022-05-24 | |
| Atenativ Effect on Uterine Blood Flow and Preeclampsia Atenativ - Antithrombin III Deficiency | Phase 4 | Withdrawn | Vastra Gotaland Region | 2016-01-01 | 2017-09-26 | |
| "Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects" none intervention - Congenital Heart Diseases, Conotruncal Defects | Unknown | Hospital Universitari Vall d'Hebron Research Institute | 300 | 2015-07-01 | 2017-03-27 | |
| A Study of KW-3357 in Congenital Antithrombin Deficiency KW-3357 - Congenital Antithrombin Deficiency | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 16 | 2009-04-01 | 2024-10-17 |
| Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate Plasma-derived AT-III concentrate - Antithrombin III Deficiency | Phase 2 / Phase 3 | Terminated | Instituto Grifols, S.A. | 3 | 2008-04-15 | 2026-10-07 |
| Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery Recombinant human antithrombin (rhAT) - Antithrombin III Deficiency | Phase 3 | Completed | rEVO Biologics | 18 | 2005-04-01 | 2012-08-17 |
| Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations. Recombinant Human Antithrombin (rhAT) - Antithrombin Deficiency, Congenital | Phase 3 | Completed | rEVO Biologics | 14 | 2002-12-01 | 2012-10-16 |
COVID-19 (1) · Congenital Disorders of Glycosylation (1) · Heart Defects, Congenital (1) · Hematologic Diseases (1) · Hemostatic Disorders (1) · Pre-Eclampsia (1) · Thrombosis (1)
Blood Coagulation Disorders (10) · Blood Coagulation Disorders, Inherited (10) · Blood Protein Disorders (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Hemic and Lymphatic Diseases (10) · Thrombophilia (10) · Hematologic Diseases (9) · Cardiovascular Diseases (3) · Vascular Diseases (2) · Carbohydrate Metabolism, Inborn Errors (1) · Cardiovascular Abnormalities (1) · Congenital Abnormalities (1) · Coronaviridae Infections (1) · Coronavirus Infections (1)
Antithrombin III (2) · Observation (1)
rEVO Biologics (2) · Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital (1) · Enrique Ginzburg (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Instituto Grifols, S.A. (1) · Kyowa Kirin Co., Ltd. (1) · Octapharma (1) · Universitair Ziekenhuis Brussel (1) · Vastra Gotaland Region (1)
United Kingdom (4) · United States (4) · France (3) · Germany (3) · Sweden (3) · Austria (2) · Canada (2) · Italy (2) · Australia (1) · Belgium (1) · Czechia (1) · Lithuania (1) · Romania (1) · Serbia (1) · Slovenia (1)
Beverley Hunt, FRCP, FRCPath MD (1) · Cambell Tait, MD (1) · Christelle Orlando, PhD (1) · Enrique Ginzburg (1) · Margareta Hellgren, MD,PhD,prof (1) · Robert C Tait, MD (1)
PMID 24335249, PMID 11057854, PMID 14719181, PMID 15500369, PMID 17636190, PMID 18226126, PMID 2329037, PMID 39207911, PMID 39911044, PMID 6484893, PMID 6618278, PMID 6872275